Table 3.
Characteristics of engaged patients by opportunity to prevent cervical cancer among women aged <70 years at diagnosis in an urban safety-net system, N = 122.
| Total N=122 (%) |
Test did not Detect Cancer n=20 (16.4%) |
No Screening n=77 (63.1%) |
No Follow-up for Abnormal Test n=25 (20.5%) |
p-valuea | ||
|---|---|---|---|---|---|---|
| Age at Cancer Diagnosis | 0.180 | |||||
| 18–29 | 5 (4.1) | 0 (0.0) | 3 (3.9) | 2 (8.0) | ||
| 30–49 | 71 (58.2) | 16 (80.0) | 38 (49.4) | 17 (68.0) | ||
| 50–64 | 43 (35.2) | 4 (20.0) | 33 (42.9) | 6 (24.0) | ||
| 65-Older | 3 (2.5) | 0 (0.0) | 3 (3.9) | 0 (0.0) | ||
| Race-Ethnicity | 0.421 | |||||
| Hispanic | 63 (51.6) | 14 (70.0) | 37 (48.1) | 12 (48.0) | ||
| Black | 37 (30.3) | 6 (30.0) | 21 (27.3) | 10 (40.0) | ||
| White | 16 (13.1) | 0 (0.0) | 13 (16.9) | 3 (12.0) | ||
| Other | 6 (4.9) | 0 (0.0) | 6 (7.8) | 0 (0.0) | ||
| Payer at Cancer Diagnosis | 0.152 | |||||
| Uninsured (Charity) | 79 (64.8) | 7 (35.0) | 58 (75.3) | 14 (56.0) | ||
| Commercial | 4 (3.3) | 1 (5.0) | 2 (2.6) | 1 (4.0) | ||
| Medicaid | 17 (13.9) | 3 (15.0) | 10 (13.0) | 4 (16.0) | ||
| Other Government | 19 (15.6) | 7 (35.0) | 6 (7.8) | 6 (24.0) | ||
| Medicare | 3 (2.5) | 2 (10.0) | 1 (1.3) | 0 (0.0) | ||
| Charlson Comorbidity Score (No Tumor) | 0.822 | |||||
| 0 | 17 (13.9) | 8 (40.0) | 6 (7.8) | 3 (12.0) | ||
| ≥ 1 | 32 (26.2) | 4 (20.0) | 21 (27.3) | 7 (28.0) | ||
| Unknown | 73 (59.8) | 8 (40.0) | 50 (64.9) | 15 (60.0) | ||
| Dallas County at Cancer Diagnosis | 0.549 | |||||
| Yes | 115 (94.3) | 20 (100) | 72 (93.5) | 23 (92.0) | ||
| No/Unknownb | 7 (5.7) | 0 (0.0) | 5 (6.5) | 2 (8.0) | ||
| Cancer Diagnosis Year | 0.032 | |||||
| 2010–2011 | 42 (34.4) | 10 (50.0) | 23 (29.9) | 9 (36.0) | ||
| 2012–2013 | 44 (36.1) | 5 (25.0) | 31 (40.3) | 8 (32.0) | ||
| 2014–2015 | 36 (29.5) | 5 (25.0) | 23 (29.9) | 8 (32.0) | ||
| Cancer Stage | 0.002 | |||||
| Local | 62 (50.8) | 16 (80.0) | 28 (36.4) | 18 (72.0) | ||
| Advanced | 58 (47.5) | 4 (20.0) | 48 (62.3) | 6 (24.0) | ||
| Not assigned | 2 (1.6) | 0 (0.0) | 1 (1.3) | 1 (4.0) | ||
| Histology | 0.096 | |||||
| Squamous | 96 (78.7) | 10 (50.0) | 65 (84.4) | 21 (84.0) | ||
| Adenocarcinoma | 21 (17.2) | 8 (40.0) | 9 (11.7) | 4 (16.0) | ||
| Adeno squamous | 3 (2.5) | 2 (10.0) | 1 (1.3) | 0 (0.0) | ||
| Carcinoma NOS/Other | 2 (1.6) | 0 (0.0) | 2 (2.6) | 0 (0.0) | ||
| Tumor Differentiation | 0.010 | |||||
| Low | 64 (52.5) | 14 (70.0) | 34 (44.2) | 16 (64.0) | ||
| High | 44 (36.1) | 4 (20.0) | 34 (44.2) | 6 (24.0) | ||
| Unknown | 14 (11.5) | 2 (10.0) | 9 (11.7) | 3 (12.0) | ||
| Initial Cancer Diagnosis Location | 0.30 | |||||
| Parkland | 110 (90.2) | 17 (85.0) | 69 (89.6) | 24 (96.0) | ||
| Elsewhere | 12 (9.8) | 3 (15.0) | 8 (10.4) | 1 (4.0) | ||
| Cancer Treatment Location | 0.045 | |||||
| All Parkland | 57 (46.7) | 12 (60.0) | 32 (41.6) | 13 (52.0) | ||
| Some Parkland | 57 (46.7) | 7 (35.0) | 39 (50.6) | 11 (44.0) | ||
| All Elsewhere | 8 (6.6) | 1 (5.0) | 6 (7.8) | 1 (4.0) | ||
| Location of First Visit during 6 Month Diagnostic Work-up Period | 0.066 | |||||
| Primary Care/ Women’s/ Specialty | 60 (49.2) | 13 (65.0) | 37 (48.1) | 10 (40.0) | ||
| Gynecology Dysplasia | 12 (9.8) | 1 (5.0) | 5 (6.5) | 6 (24.0) | ||
| Emergency Department | 50 (41.0) | 6 (30.0) | 35 (45.5) | 9 (36.0) | ||
| Number of Missed Appointments during Study Window | 0.26 | |||||
| 0 | 66 (54.1) | 13 (65.0) | 43 (55.9) | 10 (40.0) | ||
| 1 | 15 (12.3) | 2 (10.0) | 8 (10.4) | 5 (20.0) | ||
| ≥2 | 41 (33.6) | 5 (25.0) | 26 (33.8) | 10 (40.0) | ||
a
p for comparison of screen and follow-up columns
b
Four patients had unknown county of residence (N=2 no screening and N=2 no follow-up).